[Federal Register Volume 59, Number 119 (Wednesday, June 22, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-15088]


[[Page Unknown]]

[Federal Register: June 22, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

 

Revised Aggregate Production Quotas for Controlled Substances in 
Schedules I and II

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of final revised aggregate production quotas for 1994.

-----------------------------------------------------------------------

SUMMARY: This notice establishes revised 1994 aggregate production 
quotas for controlled substances in Schedules I and II of the 
Controlled Substances Act (CSA).

EFFECTIVE DATE: This order is effective on June 22, 1994.

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & 
Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) 
requires the Attorney General to establish aggregate production quotas 
for controlled substances in Schedules I and II each year. This 
responsibility has been delegated to the Administrator of the DEA 
pursuant to Sec. 0.100 of title 28 of the Code of Federal Regulations. 
The Administrator, in turn, has redelegated this function to the Deputy 
Administrator pursuant to 59 FR 23637 (May 6, 1994).
    On April 13, 1994, a notice of the proposed revised 1994 aggregate 
production quotas for certain controlled substances in Schedules I and 
II was published in the Federal Register (59 FR 17568). All interested 
parties were invited to comment on or object to these proposed 
aggregate production quotas on or before May 13, 1994.
    Several companies commented that the revised 1994 aggregate 
production quotas for amphetamine, codeine (for sale), d-
desoxyephedrine, opium, oxycodone (for sale), pentobarbital and 
secobarbital were insufficient to provide for the estimated medical, 
scientific, research and industry needs of the United States, for 
export requirements and for the establishment and maintenance of 
reserve stocks.
    The DEA has reviewed the involved companies' 1993 year-end 
inventories, their initial 1994 manufacturing quotas, 1994 export 
requirements and their actual and projected 1994 sales. Based on this 
data, the DEA has adjusted the revised 1994 aggregate production quotas 
for amphetamine, codeine (for sale), d-desoxyephedrine, opium, 
oxycodone (for sale), pentobarbital and secobarbital to meet the 
estimated medical, scientific, research and industrial needs of the 
United States.
    Regarding levorphanol, methylphenidate, phencyclidine and 
sufentanil, DEA has received updated information from several 
manufacturers which shows the necessity for adjustments of the revised 
1994 aggregate production quotas for these controlled substances. The 
adjustments will provide for the estimated medical, scientific, 
research and industrial needs of the United States and for the 
establishment and maintenance of reserve stocks. The DEA has adjusted 
the 1994 revised aggregate production quotas for levorphanol, 
methylphenidate, phencyclidine and sufentanil accordingly.
    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866. This action has been analyzed in accordance with 
the principles and criteria contained in Executive Order 12612, and it 
has been determined that this matter does not have sufficient 
Federalism implications to warrant the preparation of a Federalism 
Assessment.
    The Deputy Administrator hereby certifies that this action will 
have no significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et. seq. 
The establishment of aggregate production quotas for Schedules I and II 
controlled substances is mandated by law and by international treaty 
obligations. While aggregate production quotas are of primary 
importance to large manufacturers, their impact upon small entities is 
neither negative nor beneficial. Accordingly, the Deputy Administrator 
has determined that this action does not require a regulatory 
flexibility analysis.
    Therefore, under the authority vested in the Attorney General by 
section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), 
delegated to the Administrator of the DEA by Sec. 0.100 of title 28 of 
the Code of Federal Regulations, and redelegated to the Deputy 
Administrator pursuant to 59 FR 23637 (May 6, 1994), the Deputy 
Administrator hereby orders that the 1994 revised aggregate production 
quotas, expressed in grams of anhydrous acid or base, be established as 
follows:

------------------------------------------------------------------------
                                                            Established 
                       Basic class                         revised 1994 
                                                              quotas    
------------------------------------------------------------------------
Schedule I:                                                             
  2,5-Dimethoxyamphetamine..............................      15,510,000
Schedule II:                                                            
  Alfentanil............................................           8,000
  Amphetamine...........................................         787,000
  Codeine (for sale)....................................      61,765,000
  d-Desoxyephedrine.....................................          22,100
  Diphenoxylate.........................................         638,000
  Levorphanol...........................................           8,500
  Methylphenidate.......................................       7,313,000
  Opium.................................................       1,242,000
  Oxycodone (for sale)..................................       3,853,000
  Oxycodone (for conversion)............................           5,400
  Oxymorphone...........................................           2,420
  Pentobarbital.........................................      17,000,000
  Phencyclidine.........................................              62
  Secobarbital..........................................         550,000
  Sufentanil............................................             897
------------------------------------------------------------------------

    Dated: June 15, 1994.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 94-15088 Filed 6-21-94; 8:45 am]
BILLING CODE 4410-09-M